Advertisement
Canada markets open in 1 hour 33 minutes

  • S&P/TSX

    22,011.62
    +42.38 (+0.19%)
     

  • S&P 500

    5,116.17
    +16.21 (+0.32%)
     

  • DOW

    38,386.09
    +146.43 (+0.38%)
     

  • CAD/USD

    0.7304
    -0.0017 (-0.24%)
     

  • CRUDE OIL

    82.88
    +0.25 (+0.30%)
     

  • Bitcoin CAD

    86,000.88
    -925.06 (-1.06%)
     

  • CMC Crypto 200

    1,273.27
    -65.80 (-4.91%)
     

  • GOLD FUTURES

    2,321.40
    -36.30 (-1.54%)
     

  • RUSSELL 2000

    2,016.03
    +14.03 (+0.70%)
     

  • 10-Yr Bond

    4.6140
    -0.0550 (-1.18%)
     

  • NASDAQ futures

    17,884.00
    -20.25 (-0.11%)
     

  • VOLATILITY

    14.83
    +0.16 (+1.09%)
     

  • FTSE

    8,189.62
    +42.59 (+0.52%)
     

  • NIKKEI 225

    38,405.66
    +470.90 (+1.24%)
     

  • CAD/EUR

    0.6810
    -0.0014 (-0.21%)
     

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Business Wire
·1 min read

REDWOOD CITY, Calif. & BOSTON, April 08, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024.

Details of the event are as follows:

Panel: "Off-the-Shelf CART – Let’s Talk Lupus and Oncology"
Date: Monday, April 15, 2024
Time: 3:00 p.m. ET

The Adicet Bio team will be available for one-on-one meetings throughout the conference. Please contact your sales representative at Canaccord Genuity to register for a meeting with the company.

ADVERTISEMENT

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408693156/en/

Contacts

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com